_______________________________ Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Salix Pharmaceuticals, Inc. (NASDAQ:SLXP) have been informed by the U.S. Food and Drug Administration that the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) meeting proposed to occur on March 10-11, 2014 has been postponed to a date in the near future. The FDA informed the companies that the postponement is due to substantial scheduling conflicts. The FDA also informed the companies that it will inform the companies as soon as new dates have been secured. The FDA's action to convene an Advisory Committee to address questions surrounding the class of mu opioid antagonists being developed for opioid induced constipation was taken following a formal appeal by Salix, Progenics' collaborator, of the complete response action taken by the FDA on July 27, 2012 regarding the RELISTOR ® sNDA for opioid induced constipation in patients taking opioids who suffer from chronic pain. __________________________________________ http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0000835887-14-000018%2Etxt&FilePath=%5C2014%5C02%5C06%5C&CoName=PROGENICS+PHARMACEUTICALS+INC&FormType=8-K&RcvdDate=2%2F6%2F2014&pdf=